Andrew Dudum Sells 188,888 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $551,777.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Wednesday, July 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00.
• On Thursday, June 20th, Andrew Dudum sold 45,755 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.97, for a total value of $1,050,992.35.
• On Tuesday, June 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.88, for a total value of $3,755,093.44.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $0.84 during trading hours on Wednesday, reaching $16.04. The company’s stock had a trading volume of 12,891,685 shares, compared to its average volume of 7,830,472. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The stock has a market cap of $3.45 billion, a PE ratio of -1,604.00 and a beta of 1.08. The company’s 50-day moving average is $21.28 and its two-hundred day moving average is $15.86.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same period last year, the company earned ($0.03) EPS. The firm’s revenue for the quarter was up 51.8% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. ClariVest Asset Management LLC boosted its position in shares of Hims & Hers Health by 5,014.2% in the second quarter. ClariVest Asset Management LLC now owns 14,371 shares of the company’s stock worth $290,000 after buying an additional 14,090 shares during the period. Headlands Technologies LLC grew its stake in Hims & Hers Health by 664.2% in the second quarter. Headlands Technologies LLC now owns 112,829 shares of the company’s stock worth $2,278,000 after purchasing an additional 98,064 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at approximately $142,000. Liberty Wealth Management LLC bought a new position in shares of Hims & Hers Health in the 2nd quarter worth about $272,000. Finally, Quest Partners LLC boosted its stake in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on HIMS shares. TD Cowen boosted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Bank of America increased their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Piper Sandler restated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday. Finally, Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.57.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.